Bringing the Immune Response Back into Balance Emergo is developing treatments that target the release of inflammatory molecules, tuning down inflammation at its source. Learn more> Emergo Therapeutics announces successful completion of Phase 2a trial Emergo Therapeutics Board of Directors welcomes Jack Bailey, President, GSK Pharmaceuticals USA Emergo Announces Phase 1 Study Completion
